Form 4: Vertex Pharmaceuticals Director Acquires Shares Through Stock Option Exercise

Bruce I. Sachs, a director of Vertex Pharmaceuticals, acquired 2,398 shares of common stock through the exercise of a stock option on May 1, 2025.

Summary

• On May 1, 2025, Bruce I. Sachs, a director at Vertex Pharmaceuticals, exercised a stock option to acquire 2,398 shares of the company's common stock.
• The exercise price of the stock option was $502.97.
• Following the transaction, Sachs directly owns 2,398 shares of Vertex Pharmaceuticals common stock.
• The stock option was fully vested and expires on April 30, 2035.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding an insider transaction, and does not inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it represents a routine exercise of stock options by a company director.

Key Dates

Keywords

stock option, Form 4, VRTX, Vertex Pharmaceuticals, director, beneficial ownership, securities